scispace - formally typeset
S

Sumanth D. Prabhu

Researcher at University of Alabama at Birmingham

Publications -  201
Citations -  11834

Sumanth D. Prabhu is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Heart failure & Proinflammatory cytokine. The author has an hindex of 55, co-authored 189 publications receiving 9525 citations. Previous affiliations of Sumanth D. Prabhu include University of Alabama & Murphy Oil.

Papers
More filters
Journal ArticleDOI

The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis

TL;DR: The renin-angiotensin-aldosterone system and members of the transforming growth factor-β family play an important role in activation of infarct myofibroblasts, and therapeutic modulation of the inflammatory and reparative response may hold promise for the prevention of postinfarction heart failure.
Journal ArticleDOI

Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function

TL;DR: Intravascular injection of CSCs after reperfusion limits infarct size, attenuates LV remodeling, and ameliorates LV function, and establishes C SCs as candidates for cardiac regeneration and support an approach in which the heart's own stem cells could be collected, expanded, and stored for subsequent therapeutic repair.
Journal ArticleDOI

Animal Models of Heart Failure A Scientific Statement From the American Heart Association

TL;DR: The distinctive clinical features of the major causes of HF in humans are defined and those distinctive pathological features ofHF in humans that should be present in an animal model being used to identify fundamental causes ofHF or to test preventative or reparative therapies that could reduce HF morbidity and mortality are recommended.
Journal ArticleDOI

Cytokine-Induced Modulation of Cardiac Function

TL;DR: This review summarizes the current concepts regarding the modulation of myocardial function by cytokines and provides rationale for the sometimes-conflicting results in the literature regarding underlying mechanisms and patterns of dysfunction.
Journal ArticleDOI

Reappraising the role of inflammation in heart failure.

TL;DR: In the CANTOS trial, targeted anti-cytokine therapy with a monoclonal antibody against IL-1β resulted in improved heart failure outcomes in patients with myocardial infarction with or without established heart failure.